UBS lowered the firm’s price target on AtriCure (ATRC) to $55 from $60 and keeps a Buy rating on the shares. AtriCure posted another quarter of sales and EPS outperformance and reaffirmed 2026 guidance, but shares have come under pressure amid news of a potential competing clip launch by year-end, the analyst tells investors in a research note. The competitive moat appears underappreciated, supported by the strongest clinical dataset in the space, meaningful pull-through in open ablation procedures, and a smaller, physician-friendly form factor that enhances ease of use, UBS says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure price target lowered to $53 from $64 at Canaccord
- AtriCure: Sustained Outperformance, Manageable Competition, and Undervalued Growth Support Buy Rating and $54 Target
- Oppenheimer downgrades AtriCure on new competition from Edwards
- AtriCure downgraded to Perform from Outperform at Oppenheimer
- AtriCure price target lowered to $52 from $60 at Citizens